Literature DB >> 10625090

Blunting of pulmonary but not systemic vasodilator responses to dobutamine in newborn lambs.

J J Smolich1, T Sano, D J Penny.   

Abstract

Little is known about the changes in systemic and pulmonary vascular responses to dobutamine that occur during postnatal development. To address this question, vascular pressures and cardiac output were measured in anesthetized 1- to 2-d-old (n = 6), 7- to 10-d-old (n = 7), and 6- to 8-wk-old lambs (n = 6) while dobutamine was infused incrementally in the dose range of 0.5-40 microg x kg(-1) x min(-1). Dobutamine reduced pulmonary vascular resistance in the three age groups (all p<0.005). However, although this reduction reached a plateau over the infusion range of 15-40 microg x kg(-1) x min(-1) at all ages, its magnitude was less (p<0.02) in 1- to 2-d-old lambs (24+/-2%) than in 7- to 10-d-old (41+/-7%) or 6- to 8-wk-old lambs (42+/-6%). Over the same infusion range, dobutamine produced a fall in systemic vascular resistance (all p<0.005) that was proportionally similar in 1- to 2-d-old (51+/-3%), 7- to 10-d-old (48+/-3%), and 6- to 8-wk-old lambs (42+/-6%). In separate subgroups of 1- to 2-d-old lambs, pulmonary and systemic responses to dobutamine were not affected by pretreatment with selective alpha1-, beta1-, or beta2-adrenoceptor antagonists. Taken together, these findings suggest that the pulmonary but not systemic vasodilator response to dobutamine in lambs is blunted in the initial days after birth, and that this pulmonary effect is not directly related to the adrenoceptor-stimulating properties of dobutamine.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10625090     DOI: 10.1203/00006450-200001000-00019

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  1 in total

Review 1.  Dobutamine in paediatric population: a systematic review in juvenile animal models.

Authors:  Victoria Mielgo; Adolf Valls i Soler; Carmen Rey-Santano
Journal:  PLoS One       Date:  2014-04-22       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.